CTLA4 and melanoma: Several cases of opportunistic infections among patients with melanoma receiving the CTLA-4 inhibitor ipilimumab have been published, including invasive aspergillosis [63], cytomegalovirus-induced hepatitis [64], and pneumocystis pneumonia (PJP) [65].